{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:02:54Z","timestamp":1791349374492,"version":"4.3.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1-3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ejphar.2013.05.014","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T07:32:47Z","timestamp":1369294367000},"page":"246-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":276,"title":["Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice"],"prefix":"10.1016","volume":"715","author":[{"given":"Atsuo","family":"Tahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Yokono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamajuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hayashizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Sasamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2013.05.014_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"12","author":"Abdul-Ghani","year":"2012","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.ejphar.2013.05.014_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2013.05.014_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2001-12931","article-title":"Treatment of nonalcoholic fatty liver: present and emerging therapies","volume":"21","author":"Angulo","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ejphar.2013.05.014_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000115118","article-title":"Hyperglycemia and the pathobiology of diabetic complications","volume":"45","author":"Aronson","year":"2008","journal-title":"Adv. Cardiol."},{"key":"10.1016\/j.ejphar.2013.05.014_bib5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.clinbiochem.2007.02.006","article-title":"Oxidative stress and antioxidant defenses in serum of patients with non-\u03b1lcoholic steatohepatitis","volume":"40","author":"Baskol","year":"2007","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejphar.2013.05.014_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.7326\/0003-4819-142-6-200503150-00006","article-title":"Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes","volume":"142","author":"Boden","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2013.05.014_bib7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.ijo.0802943","article-title":"Fenofibrate prevents rosiglitazone-induced body weight gain in ob\/ob mice","volume":"29","author":"Carmona","year":"2005","journal-title":"Int. J. Obesity"},{"key":"10.1016\/j.ejphar.2013.05.014_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.ejphar.2013.05.014_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1444-0903.2004.00574.x","article-title":"Nonalcoholic fatty liver disease: is all the fat bad?","volume":"34","author":"Clouston","year":"2004","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.ejphar.2013.05.014_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2013.05.014_bib11","first-page":"20","article-title":"Diabetes update","volume":"38","author":"Dwarakanathan","year":"2006","journal-title":"J. Insur. Med."},{"key":"10.1016\/j.ejphar.2013.05.014_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.ejphar.2013.05.014_bib13","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/oby.2009.388","article-title":"Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials","volume":"17","author":"Horton","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2013.05.014_bib14","first-page":"285","article-title":"Sodium\u2013glucose cotransporter inhibitors for diabetes","volume":"8","author":"Isaji","year":"2007","journal-title":"Curr. opinion Invest. Drugs"},{"key":"10.1016\/j.ejphar.2013.05.014_bib15","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.intimp.2011.01.036","article-title":"Anti-inflammatory effect of genistein on non-\u03b1lcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms","volume":"11","author":"Ji","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2013.05.014_bib16","first-page":"298","article-title":"Beta-cell dysfunction with chronic hyperglycemia: \u201coverworked beta-cell\u201d hypothesis","volume":"4","author":"Leahy","year":"1996","journal-title":"Diabetes Rev."},{"key":"10.1016\/j.ejphar.2013.05.014_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2337\/diacare.15.3.442","article-title":"Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion","volume":"15","author":"Leahy","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2013.05.014_bib18","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2013.05.014_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12291-009-0075-1","article-title":"Attenuation of oxidative stress in streptozotocin-induced diabetic rats by eucalyptus globulus","volume":"24","author":"Nakhaee","year":"2009","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.ejphar.2013.05.014_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc08-9016","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2013.05.014_bib21","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1016\/S0021-9258(19)50557-9","article-title":"Cloning and functional expression of a mammalian Na+\/nucleoside cotransporter. A member of the SGLT family","volume":"267","author":"Pajor","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2013.05.014_bib22","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1053\/j.gastro.2007.03.055","article-title":"Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease","volume":"132","author":"Parekh","year":"2007","journal-title":"Gastroenterology"},{"issue":"supple 1","key":"10.1016\/j.ejphar.2013.05.014_bib23","first-page":"A176","article-title":"Canagliflozin treatment improves beta cell function in subject with type 2 diabetes","volume":"59","author":"Polidori","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2013.05.014_bib24","first-page":"255","article-title":"Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus","volume":"18","author":"Rossetti","year":"1995","journal-title":"Clin. Invest. Med."},{"key":"10.1016\/j.ejphar.2013.05.014_bib25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3797\/scipharm.1104-21","article-title":"Type 2 diabetes mellitus-induced hyperglycemia in patients with NAFLD and normal LFTs: relationship to lipid profile, oxidative stress and pro-inflammatory cytokines","volume":"79","author":"Shams","year":"2011","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.ejphar.2013.05.014_bib26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1046\/j.1464-5491.1999.00110.x","article-title":"Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-\u03b1cting versus short-\u03b1cting sulphonylureas","volume":"16","author":"Stahl","year":"1999","journal-title":"Diabetic Med."},{"key":"10.1016\/j.ejphar.2013.05.014_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2013.05.014_bib28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","article-title":"Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo","volume":"385","author":"Tahara","year":"2012","journal-title":"Naunyn\u2013Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2013.05.014_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejphar.2011.01.015","article-title":"Effects of antidiabetic drugs in high-fat diet and streptozotocin\u2013nicotinamide-induced type 2 diabetic mice","volume":"655","author":"Tahara","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2013.05.014_bib30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1046\/j.1464-5491.2001.00534.x","article-title":"Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in Type 2 diabetes","volume":"18","author":"Taverna","year":"2001","journal-title":"Diabetic Med"},{"key":"10.1016\/j.ejphar.2013.05.014_bib31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2013.05.014_bib32","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.2337\/diabetes.52.12.2882","article-title":"Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects","volume":"52","author":"Tripathy","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2013.05.014_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/350354a0","article-title":"Glucose\/galactose malabsorption caused by a defect in the Na+\/glucose cotransporter","volume":"350","author":"Turk","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2013.05.014_bib34","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2013.05.014_bib35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00439-002-0820-5","article-title":"Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)","volume":"111","author":"van den Heuvel","year":"2002","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ejphar.2013.05.014_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/CS20060150","article-title":"Diet, obesity and diabetes: a current update","volume":"112","author":"Walker","year":"2007","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ejphar.2013.05.014_bib37","first-page":"F459","article-title":"Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter","volume":"263","author":"Wells","year":"1992","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2013.05.014_bib38","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00424-003-1063-6","article-title":"The sodium\/glucose cotransport family SLC5","volume":"447","author":"Wright","year":"2004","journal-title":"Pflugers Arch.\u2014Eur. J. Physiol."},{"key":"10.1016\/j.ejphar.2013.05.014_bib39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/diacare.25.2.376","article-title":"Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients","volume":"25","author":"Yang","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2013.05.014_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1463-1326.2010.01216.x","article-title":"Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight","volume":"12","author":"Zhang","year":"2010","journal-title":"Diabetes Obesity Metab."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299913003993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299913003993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T18:15:39Z","timestamp":1645553739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299913003993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":40,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0014299913003993"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2013.05.014","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2013.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}